We have used an RNA based mutation detection method to screen the total coding region of the dystrophin gene of a Duchenne and a Becker muscular dystrophy patient in whom DNA based mutation detection methods have so far failed to detect mutations. By RT-PCR Screening for the remaining one-third of mutations is often done by SSCP or heteroduplex analysis using multiplex PCR products.7"-Until now, no clustering of small mutations has been found.'2 Although there is a higher concentration of mutations 3' of exon 55, this is consistent with the high number of CGA codons which are more likely to mutate to a TGA." Strikingly, assuming a random distribution of point mutations over the coding region, the percentage of point mutations identified so far by DNA based studies is far below the percentage expected.7"-Screening between 20% and 80% of the coding region showed only 2-18% mutations.
detection method to screen the total coding region of the dystrophin gene of a Duchenne and a Becker muscular dystrophy patient in whom DNA based mutation detection methods have so far failed to detect mutations. By RT-PCR and the protein truncation test (PTT) we could identify point mutations in both cases. DMD patient DL184.3 has a T-*A mutation in intron 59 at position -9, creating a novel splice acceptor site for exon 60. As a result seven intronic bases are spliced into the mRNA, causing a frameshift and premature translation termination 20 codons downstream. Since this patient had died and only fibroblasts were available, we applied MyoD induced myodifferentiation of stored fibroblasts to enhance muscle specific gene expression. With the results of this mutation analysis, prenatal diagnosis could subsequently be performed in this family. BMD patient BL207.1 carries a G-C mutation at position + 5 of intron 64, disrupting the splice donor consensus sequence and activating a cryptic splice donor site 57 bp downstream. The inclusion of these 57 intronic bases in the mRNA leaves the reading frame open and results in the insertion of 19 amino acids into the cysteine rich domain of dystrophin. Interestingly, this insertion in a part of the dystrophin considered to interact with the dystrophin binding complex of the sarcolemma is apparently compatible with mild BMD-like clinical features. Both mutations reported are missed by analysis ofmultiplex PCR products designed for deletion screening of the coding region. Extrapolation from existing point mutation detection efficiencies by DNA and RNA based methods emphasises that RNA based methods are more sensitive and that most of the remaining undetected mutations may affect splice or branch sites or Screening for the remaining one-third of mutations is often done by SSCP or heteroduplex analysis using multiplex PCR products.7"-Until now, no clustering of small mutations has been found.'2 Although there is a higher concentration of mutations 3' of exon 55, this is consistent with the high number of CGA codons which are more likely to mutate to a TGA." Strikingly, assuming a random distribution of point mutations over the coding region, the percentage of point mutations identified so far by DNA based studies is far below the percentage expected.7"-Screening between 20% and 80% of the coding region showed only 2-18% mutations.
One possible explanation is that the deletion hotspots covered by the multiplex PCR commonly used for point mutation screening are relatively sparse in point mutations. More likely, however, the remaining mutations are splicing mutations located outside the coding region usually screened. Indeed, 14 out of the 36 multiplex primers are either located inside an exon or cover or flank intron-exon boundaries and thus do not permit the detection of mutations affecting splice sites.
Using RNA based mutation detection methods, a much higher percentage of mutations is identified. By screening the total coding region, mutations have been found in seven out of seven patients (100%)'3 and 16 out of 22 (73%). 14 We present a study in which the entire dystrophin gene of a DMD and a BMD patient was screened for mutations. For this purpose we performed RT-PCR followed by a protein truncation test (PTT) , that is, in vitro transcription/translation of RT-PCR products. 15 Not all parts of the dystrophin gene of patient DL184.3 could be amplified on RNA isolated from fibroblasts (the patient has died and no RNA from peripheral blood lymphocytes was available). Therefore, we performed MyoD transfection and myodifferentiation on his fibroblasts. Fibroblast were transfected with a MyoD gene (a regulator of myogenesis) in a retroviral vector and selected for vector derived neomycin resistance. Induction of myogenesis by transfer to low serum conditions increases the amount of dystrophin transcripts in RNA from these cells.'6 Subsequently, in both the DMD and the BMD patient, a mutation was identified which interferes with normal splicing. The site of the mutation was in both cases located in an intron and would not have been identified with the currently used DNA based methods.
Material and methods

CELL CULTURE AND FORCED MYODIFFERENTIATION
Fibroblasts of patient DL184.3, kindly provided by Dr W Kleyer, Cellbank Rotterdam, were grown in DMEM (Gibco-BRL, UK) without phenol red, supplemented with 10% FCS. They were infected with a MyoD containing retrovirus and differentiation was induced as previously described."6 The efficiency of differentiation was tested by immunohistochemical detection of desmin, titin, and the appearance of cell fusion. No dystrophin could be detected, confirming the clinical diagnosis of DMD.
MUTATION DETECTION
For patient DL184.3 total RNA was isolated from myodifferentiated cell pellets using RNAsol (Cinna/Biotecx Laboratories, USA). For patient BL207. 1 peripheral blood lymphocytes were isolated from total blood using histopaq (Sigma, USA), RNA was isolated, and RT-PCR was performed as previously described. '6 The protein truncation test (PTT) was performed as previously published.'5 Sequence analysis was performed using a PCR product sequencing kit (USB, USA). To confirm the presence of mutations detected, genomic DNA was amplified using a primer in the intron sequences and sequenced as described. in a truncated protein while the mutation in Becker patient BL207.1 results in a slightly larger protein. Western blot analysis of a muscle biopsy from BL207.1 showed a reduced amount of apparently normal sized dystrophin (data not shown). The latter is plausible since the inclusion of 19 amino acids does not significantly alter the length of a 427 kDa protein.
The decreased amount of dystrophin suggests, besides a possibly less efficient splicing of the cryptic splice site causing a reduced amount of mRNA, that the enlarged protein may be somewhat less stably anchored to the membrane than the normal dystrophin and probably less functional. The 19 inserted amino acids, NYWPVFEDLDTMSLLRIKM, consist of nine hydrophillic and 10 hydrophobic amino acids of which three are acidic and two basic, which makes it a neutral insertion without particular 3D folding properties. The insertion is located in the cysteine rich domain of the dystrophin, which binds to the dystrophin binding glycoprotein complex.20 Considering the mild BMD phenotype, this insertion is apparently without any major disruptive effect on the function of dystrophin. While we cannot formally exclude the existence of yet another mutation causing the BMD phenotype an extensive search for deletions or point mutations has not yielded any results. Moreover, if another BMD mutation exists this would imply that the insertion itself is entirely inconsequential. Considering both these points, the more plausible hypothesis for the cause of the BMD phenotype is the 19AA insertion. Thus, this insertion is at least compatible with mild dystrophic function and possibly, but unlikely, with normal function, but clearly, against expectation, does not cause severe DMD.
The mutation also effects the Dp 140, ofthe coding region using RNA based mutation screening. This mutation was missed using multiplex PCR/SSCP analysis, since it is located at the end of exon 43 and covered by the reverse primer used to amplify the exon. Although the multiplex products cover 20% of the dystrophin coding region, DNA based methods only detect mutations in 4% of nondeletion patients (table 1) . RNA based methods, screening the total coding region, identify mutations in 82% of the patients (table  2) . The number of mutations identified by RNA based methods21-4 1627 29-31 (this study) is still limited; however, seven mutations out of 31 found (23%) are located in that 20% of the coding sequence which is covered by multiplex PCR. This suggests that this region is not particularly sparse in point mutations.
Of the mutations identified with multiplex based PCR material, 18% affect splice sites (table 1), while in RNA based mutation screening studies as much as 29% of the mutations affect splicing ( We want to point out that another possible reason for missing mutations affecting splicing is that they produce transcripts too large to be detected by RT-PCR. Indeed, since most splice site mutations are leaky and produce low levels of correctly spliced products, normal transcripts covering the mutation site will be detected as the only product and the mutation will be missed. We are currently studying a potential example of such an event: a BMD patient with an intron 17 derived insertion in a portion of his dystrophin RNA. No mutation can yet be detected, and the altered transcript might just represent a splice alternative generated by an intronic mutation that produces transcripts too large to amplify.
In conclusion we believe, as emphasised by the mutations identified in this report, that many of the remaining elusive DMD/BMD mutations will be located outside the coding region and affect splicing.
